IAP12 Rec'd PCT/PTO 2 9 APR 2006

"Express Mail" mailing label number & L 832 895 378 U.S	
"Express Mail" mailing label number 22, 2006	
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Ma to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissic Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Desp. Thomas Signature	il Post Office oner for
Printed Name Signature	

PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	CAMPBELL, Gordon Iain, et al.)
National Phase of PCT Serial No.	:	PCT/US2004/032771)
International Filing Date	:	October 28, 2004)
For	:	MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS))
Docket No		X15830)

INFORMATION DISCLOSURE STATEMENT SUBMITTED SIMULTANEOUSLY WITH NATIONAL PHASE ENTRY

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner. This form is being submitted simultaneously with the U.S. national phase entry for the above-identified PCT application.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

IAP12 Rec'd PCT/PTO 2 9 APR 2006

Applicants respectfully request consideration of this information.

Respectfully submitted,

Charles E. Cohen, Ph.D. Attorney for Applicants

Registration No. 34,565

Phone: 317-433-4983

Eli Lilly and Company Patent Division/CEC P.O. Box 6288 Indianapolis, Indiana 46206-6288

IAP12 Rec'd PCT/PTO 29 APR 2006

Sheet 1 of 1

FORM PTO 1449 (modified)	Atty. Docket No. X15830	International Serial No PCT/US2004/032771	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant CAMPBELL, Gordon lain		
	International Application Date October 28, 2004 US Nat'l Entry (if applicable)	Group Art Unit	

Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO 99/37305	07-29-1999	Morgan et al.		
	ВВ	WO 01/00214	01-04-2001	Hunt et al.		
	BC	WO 01/01973	01-11-2001	Wong et al.		
	BD	WO 03/018576	03-06-2003	Gustafsson et al.	·	
	BE	WO 2004/018441	03-04-2004	Thomas et al.		
-	BF	FR 2 852 954	10-01-2004	Aventis		
	BG	JP 2004 277318	10-07-2004	Dainippon		
	ВН	WO 2004/087647	10-14-2004	Aventis		
NON PA	TENT	LITERATURE DO		O title of the estiele (when	appropriate), title of the item	
Initials*	No. 1	(book, magazine, journal, s	serial, symposium, catalog	g, etc.), date, page(s), voluntry where published.	ne-issue number(s) publisher,	Т ⁶
	CA International Search Report					
	СВ	KATO, Shiro, et al., "1-(1-Substituted-4-piperidinylmethyl)piperidine derivatives as 5-TH4 receptor agonists, pharmaceutical compositions containing them, and their use," XP002317575, DATABASE CA 'Online! Chemical Abstracts Service, Columbus, Ohio, US, retrieved from STN Database accession no. 2004:819908 abstract.				
	CC	KING, Frank, et al., "their elaboration to 1-32(20):2281-4, 1991.				-

		<u> </u>	
Examiner		Date Considered	<u>-</u>
Signature	·		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.